Be a Smart Investor
Tuesday, January 10, 2017
Gilead CEO: M&A is top of mind for us this year
John Milligan, Gilead president and CEO, speaks to CNBC's Meg Tirrell about potential M&A, drug-pricing pressure under President-elect Donald Trump and the company's hepatitis C drugs.
from Mergers and Acquisitions http://ift.tt/2j5wb2x
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment